OCMS Bio

OCMS Bio is a private, preclinical-stage biotechnology company leveraging a proprietary, high-throughput mammalian cell screening platform integrated with AI to discover and engineer best-in-class antibody therapeutics. Founded in 2018 and headquartered in King of Prussia, Pennsylvania, the company aims to overcome the limitations of traditional antibody discovery by prioritizing functional efficacy early in the process. Its leadership includes seasoned veterans from Immunome and the biopharma industry, and it is advancing an internal pipeline while seeking strategic partnerships.

AI-integrated, high-throughput mammalian cell screening platform for 'function-first' antibody discovery and engineering, enabling rapid identification of candidates optimized for binding, immunogenicity, stability, and biological activity.

OCMS Bio competes in the crowded field of AI/ML-enabled biotech discovery platforms (e.g., Absci, Generate Biomedicines, Recursion) and traditional antibody discovery service providers. Its key claimed differentiation is the direct, high-throughput functional screening in mammalian cells, aiming to reduce translational failures common in other platforms.